Olanzapine-induced rhabdomyolysis

Area of Science:

• Pharmacology
• Neurology
• Toxicology

Background:

• Neuroleptic malignant syndrome (NMS) is a rare but serious condition associated with antipsychotic medications.
• Rhabdomyolysis, a condition involving muscle breakdown, can occur in NMS.

Purpose of the Study:

• To report a case of olanzapine-induced rhabdomyolysis without other NMS features.
• To discuss the potential for distinct pathophysiological mechanisms of isolated rhabdomyolysis versus NMS-associated rhabdomyolysis.
• To explore implications for drug rechallenge strategies.

Main Methods:

• Case report presentation.
• Review of existing literature on olanzapine, rhabdomyolysis, and NMS.

Main Results:

• A patient developed rhabdomyolysis potentially linked to olanzapine use.
• The patient did not exhibit other characteristic symptoms of NMS.
• Literature suggests differing mechanisms for isolated rhabdomyolysis compared to NMS-related cases.

Conclusions:

• Olanzapine may cause rhabdomyolysis independently of NMS.
• Differentiating the cause of rhabdomyolysis is crucial for patient management and future treatment decisions.
• Further research into the specific mechanisms is warranted to guide safe drug rechallenge.